Last reviewed · How we verify
Acute Lymphoblastic Leukemia (ALL) in pediatric patients
Approved treatments
- Asparlas · Pfizer
Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute Lymphoblastic Leukemia (ALL) in pediatric patients patent landscape — cliff calendar, originator estates, attackable patents
- Acute Lymphoblastic Leukemia (ALL) in pediatric patients treatment landscape brief
- Acute Lymphoblastic Leukemia (ALL) in pediatric patients treatment updates RSS
Frequently asked questions about Acute Lymphoblastic Leukemia (ALL) in pediatric patients
What drugs treat Acute Lymphoblastic Leukemia (ALL) in pediatric patients?
Tracked treatments include Asparlas.
What is the treatment for Acute Lymphoblastic Leukemia (ALL) in pediatric patients?
Standard treatment for Acute Lymphoblastic Leukemia (ALL) in pediatric patients includes Asparlas. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute Lymphoblastic Leukemia (ALL) in pediatric patients patent cliff · Acute Lymphoblastic Leukemia (ALL) in pediatric patients CI report
- Treatment: Asparlas · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing